Form 4: Pliant Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

Eric Lefebvre, Chief Medical Officer of Pliant Therapeutics, sold 12,319 shares of common stock to cover withholding tax obligations related to vesting performance-vested stock units.

Summary

• On July 10, 2024, Eric Lefebvre, the Chief Medical Officer of Pliant Therapeutics, sold 12,319 shares of common stock.
• The sale was executed at a price of $11.56 per share.
• The transaction was a non-discretionary sale by the plan to satisfy withholding tax liability in connection with the vesting of previously granted performance-vested stock units.
• Following the transaction, Lefebvre directly owns 213,052 shares of Pliant Therapeutics.
• The sale was conducted under a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and does not indicate any significant positive or negative sentiment.

Industry Context

Sales of shares to cover tax obligations upon vesting of stock options or restricted stock units are a common practice among corporate executives. These sales are often conducted under pre-arranged trading plans (Rule 10b5-1) to avoid accusations of insider trading.

Comparison to Industry Standards

• Similar sales for tax obligations are common across the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Biogen often see similar filings from their executives.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although it is a common practice for covering tax obligations.

Key Dates